{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:53:16Z","timestamp":1769640796023,"version":"3.49.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/wnf.0b013e3181a9eb1b","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T08:16:32Z","timestamp":1259741792000},"page":"353-354","source":"Crossref","is-referenced-by-count":26,"title":["Pregabalin-Induced Parkinsonism"],"prefix":"10.1097","volume":"32","author":[{"given":"Santiago","family":"Perez Lloret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariela","family":"Amaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Merello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210203","first-page":"757","article-title":"Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance.","volume":"150","author":"Llau","year":"1994","journal-title":"Rev Neurol (Paris)"},{"key":"R2-13-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0002-9343(99)80104-1","article-title":"Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study.","volume":"99","author":"Avorn","year":"1995","journal-title":"Am J Med"},{"key":"R3-13-20210203","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.21854","article-title":"Failure of recognition of drug-induced parkinsonism in the elderly.","volume":"23","author":"Esper","year":"2008","journal-title":"Mov Disord"},{"key":"R4-13-20210203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00002512-199405020-00006","article-title":"Drug-induced parkinsonism in the aged. Recognition and prevention.","volume":"5","author":"Gershanik","year":"1994","journal-title":"Drugs Aging"},{"key":"R5-13-20210203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/1353-8020(96)00013-2","article-title":"Drug-induced parkinsonism in a movement disorders unit: a four-year survey.","volume":"2","author":"Jimenez-Jimenez","year":"1996","journal-title":"Parkinsonism Relat Disord"},{"key":"R6-13-20210203","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/14740338.5.6.759","article-title":"Drug-induced parkinsonism.","volume":"5","author":"Mena","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"R7-13-20210203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2007.01.013","article-title":"Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.","volume":"29","author":"Tassone","year":"2007","journal-title":"Clin Ther"},{"key":"R9-13-20210203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery.","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res"},{"key":"R10-13-20210203","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1059-1311(02)00295-9","article-title":"Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations.","volume":"12","author":"Errante","year":"2003","journal-title":"Seizure"},{"key":"R11-13-20210203","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.seizure.2005.11.005","article-title":"Pregabalin: a new antiepileptic drug for refractory epilepsy.","volume":"15","author":"Hamandi","year":"2006","journal-title":"Seizure"},{"key":"R12-13-20210203","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2006.09.019","article-title":"Pregabalin action at a model synapse: binding to presynaptic calcium channel alpha2-delta subunit reduces neurotransmission in mice.","volume":"553","author":"Joshi","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"R13-13-20210203","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(03)00173-8","article-title":"Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C.","volume":"105","author":"Fehrenbacher","year":"2003","journal-title":"Pain"},{"key":"R14-13-20210203","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1353-8020(98)00032-7","article-title":"Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson's disease.","volume":"4","author":"Garcia-Ruiz","year":"1998","journal-title":"Parkinsonism Relat Disord"},{"key":"R15-13-20210203","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/S0004-282X2004000500008","article-title":"Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine.","volume":"62","author":"Fabiani","year":"2004","journal-title":"Arq Neuropsiquiatr"},{"key":"R16-13-20210203","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neuropharm.2005.03.003","article-title":"Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.","volume":"49","author":"Serrano","year":"2005","journal-title":"Neuropharmacology"},{"key":"R17-13-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mds.870120119","article-title":"A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism.","volume":"12","author":"Negrotti","year":"1997","journal-title":"Mov Disord"},{"key":"R18-13-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neuron.2007.06.023","article-title":"Parkinson's disease: return of an old prime suspect.","volume":"55","author":"Sulzer","year":"2007","journal-title":"Neuron"},{"key":"R19-13-20210203","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/j.1460-9568.2007.05803.x","article-title":"Substance P excites globus pallidus neurons in vivo.","volume":"26","author":"Cui","year":"2007","journal-title":"Eur J Neurosci"},{"key":"R20-13-20210203","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neures.2007.10.007","article-title":"Effects of substance P on neuronal firing of pallidal neurons in parkinsonian rats.","volume":"60","author":"Cui","year":"2008","journal-title":"Neurosci Res"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e3181a9eb1b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:14:08Z","timestamp":1620976448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200911000-00013"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181a9eb1b","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}